Scarica l'app Stockscreener
0.1703
5.25%
0.0085
Dopo l'orario di chiusura:
.17
-0.0003
-0.18%
AIM ImmunoTech Inc Borsa (AIM) Ultime notizie
AIM ImmunoTech Highlights Recent Media Coverage of - GlobeNewswire
AIM ImmunoTech Highlights Recent Media Coverage of - GlobeNewswire
AIM ImmunoTech Spotlights Growing Attention Around - GlobeNewswire
57 patients with stable pancreatic cancer received an immune-modulating drug after chemotherapy. - Stock Titan
AIM ImmunoTech Spotlights Growing Attention Around - GlobeNewswire
AIM ImmunoTech Discusses Ampligen®’s Potential to - GlobeNewswire
AIM ImmunoTech Announces Virtual 2026 Annual Stockholders Meeting and Proxy Details - Kalkine Media
AIM ImmunoTech Submits 2025 Annual Report Highlighting Focus on Ampligen for Pancreatic Cancer - Kalkine Media
AIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video - The Manila Times
A 39-patient exploratory analysis reported 34.8 months’ median survival in pancreatic cancer. - Stock Titan
AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib - markets.businessinsider.com
AIM Looks 71.3% Undervalued on GF Value™ Despite Financial Strug - GuruFocus
AIM ImmunoTech Highlights Ampligen’s Potential Role in the - globenewswire.com
AIM ImmunoTech Inc Share PriceAIM, RNS News, Articles, Quotes, & Charts (AMEX:AIM) - Proactive financial news
Aim Immunotech Stock Price Forecast. Should You Buy AIM? - StockInvest.us
Aim ImmunoTech CEO Equels buys $4,992 in stock - Investing.com
Aim ImmunoTech CEO & president buys $2,310 in company stock - Investing.com
Aim ImmunoTech CEO & President Thomas Equels buys $4,862 in stock - Investing.com
AIM ImmunoTech Reduces Debt via Equity Exchange Agreements - The Globe and Mail
AIM ImmunoTech Reduces Debt via Equity Exchange Agreements - TipRanks
AIM ImmunoTech Converts ~$450,000 of Note Into 1.92M Shares in Exchanges With Streeterville - TradingView
AIM ImmunoTech Highlights Scientific Rationale, Supportive - GlobeNewswire
AIM ImmunoTech Highlights Scientific Rationale, Supportive - GlobeNewswire
AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video - Yahoo Finance
AIM ImmunoTech Eliminates $1.22 Million Debt via Stock Exchange - minichart.com.sg
AIM ImmunoTech Extinguishes Debt Through Equity Exchanges - TipRanks
AIM ImmunoTech Secures Ampligen Patent Protection in Europe - Intellectia AI
AIM ImmunoTech Significantly Expands Ampligen® Global - GlobeNewswire
AIM ImmunoTech Significantly Expands Ampligen® Global - GlobeNewswire
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041 - The Manila Times
AIM ImmunoTech Secures European and U.K. Patent Protection for Ampligen in Long COVID Through 2041 - Quiver Quantitative
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041 - Yahoo Finance
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041 - GlobeNewswire
AIM ImmunoTech Extends IP Protection for Ampligen Through 2039 with Broad US Patent - Contract Pharma
AIM Looks 69.6% Undervalued on GF Value™ Despite Financial Distr - GuruFocus
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039 - The Manila Times
AIM ImmunoTech Secures U.S. Patent for Ampligen Combination with Pembrolizumab in Cancer Treatment - Quiver Quantitative
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod - GlobeNewswire
AIM patent covers Ampligen with Keytruda across cancers through 2039 - Stock Titan
AIM Q2 2026 Earnings: Wider Than-Expected Loss as Clinical-Stage Costs PersistProfit Inflection Point - vinanet.vn
AIM ImmunoTech Inc. (AIM) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
AIM ImmunoTech Inc. (AIM) Key Financial Ratios – Valuation, Profitability & More - Value Research
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference - manilatimes.net
AIM ImmunoTech doses final patient in pancreatic cancer trial - stocktitan.net
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference - Yahoo Finance
AIM ImmunoTech Participates in the Virtual Investor 'Why Now' On-Demand Conference - Moomoo
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference - GlobeNewswire
AIM | AIM ImmunoTech Inc. FinancialsRevenue Breakdown - quiverquant.com
AIM ImmunoTech (AIM) Stock Forecast & Analyst Ratings - Moomoo
AIM Maintained by Ascendiant Capital -- Price Target Lowered to $7.00 - GuruFocus
1.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):